Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Altern Ther Health Med ; 29(8): 489-495, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37652420

RESUMEN

Objective: Dry eye syndrome after cataract surgery is a common complication that may affect the patient's visual comfort and quality of life. Because the surgery may affect the secretion and quality of tears in the eye, resulting in dry and uncomfortable eyes.This study aimed to investigate the therapeutic effects of recombinant bovine basic fibroblast growth factor (rb-bFGF) eye drops on dry eye syndrome after cataract surgery and to analyze its impact on tear secretion and corneal injury. Methods: This is a retrospective study. A total of 126 patients (126 eyes) with dry eye syndrome after cataract surgery were treated between January 2021 and October 2022. patients were randomly divided into a study group (64 patients, 64 eyes) and a control group (62 patients, 62 eyes). Both groups were treated with sodium hyaluronate eye drops, while the study group received rb-bFGF eye drops for four weeks in addition to the sodium hyaluronate eye drops. The clinical efficacy, results of tear secretion test (SIT), tear film break-up time (BUT), corneal fluorescein staining, corneal topography examination, oxidative stress indicators, ocular surface disease index (OSDI) score, and drug adverse reactions were compared between the two groups. Results: The study group exhibited a significantly higher total effective treatment rate (96.88%) compared to the control group (85.48%), suggesting the enhanced efficacy of rb-bFGF eye drops. Moreover, the study group demonstrated extended tear secretion length and tear film break-up time, indicating improved tear film stability and ocular surface health. Additionally, the study group showed reduced corneal fluorescein staining score and improved corneal surface regularity index, indicative of enhanced corneal integrity and smoothness. Notably, tear superoxide dismutase levels were elevated, while lipid peroxide levels were lowered in the study group, underscoring the potential antioxidative effects of rb-bFGF. The study group also exhibited a lower OSDI score, suggesting reduced ocular discomfort and improved quality of life. Although the study group had a slightly higher incidence of adverse reactions (9.38%) compared to the control group (8.06%), the difference was not statistically significant. Particularly significant is the statistical significance highlighting the heightened total effective treatment rate in the study group, indicating the potential of rb-bFGF eye drops in promoting favorable therapeutic outcomes. Conclusion: rb-bFGF eye drops are safe and effective in treating dry eye syndrome after cataract surgery. They can help regulate tear secretion, repair corneal damage, and improve dry eye symptoms. Despite the retrospective design and relatively small sample size of this study, further randomized controlled trials and larger sample size may be needed to verify the robustness of the results, but this study is important for guiding the treatment strategy and optimizing patient care for dry eye after cataract surgery.


Asunto(s)
Catarata , Lesiones de la Cornea , Síndromes de Ojo Seco , Humanos , Animales , Bovinos , Soluciones Oftálmicas/uso terapéutico , Ácido Hialurónico/uso terapéutico , Estudios Retrospectivos , Calidad de Vida , Síndromes de Ojo Seco/tratamiento farmacológico , Fluoresceína/uso terapéutico , Catarata/complicaciones , Catarata/tratamiento farmacológico , Lesiones de la Cornea/complicaciones , Lesiones de la Cornea/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto
2.
Transl Vis Sci Technol ; 12(5): 20, 2023 05 01.
Artículo en Inglés | MEDLINE | ID: mdl-37204800

RESUMEN

Purpose: The corneal epithelium has a glycocalyx composed of membrane-associated glycoproteins, mucins, and galactin-3. Similar to the glycocalyx in visceral tissues, the corneal glycocalyx functions to limit fluid loss and minimize frictional forces. Recently, the plant-derived heteropolysaccharide pectin has been shown to physically entangle with the visceral organ glycocalyx. The ability of pectin to entangle with the corneal epithelium is unknown. Methods: To explore the potential role of pectin as a corneal bioadhesive, we assessed the adhesive characteristics of pectin films in a bovine globe model. Results: Pectin film was flexible, translucent, and low profile (80 µm thick). Molded in tape form, pectin films were significantly more adherent to the bovine cornea than control biopolymers of nanocellulose fibers, sodium hyaluronate, and carboxymethyl cellulose (P < 0.05). Adhesion strength was near maximal within seconds of contact. Compatible with wound closure under tension, the relative adhesion strength was greatest at a peel angle less than 45 degrees. The corneal incisions sealed with pectin film were resistant to anterior chamber pressure fluctuations ranging from negative 51.3 ± 8.9 mm Hg to positive 214 ± 68.6 mm Hg. Consistent with these findings, scanning electron microscopy demonstrated a low-profile film densely adherent to the bovine cornea. Finally, the adhesion of the pectin films facilitated the en face harvest of the corneal epithelium without physical dissection or enzymatic digestion. Conclusions: We conclude that pectin films strongly adhere to the corneal glycocalyx. Translational Relevance: The plant-derived pectin biopolymer provides potential utility for corneal wound healing as well as targeted drug delivery.


Asunto(s)
Lesiones de la Cornea , Animales , Bovinos , Fenómenos Biomecánicos , Lesiones de la Cornea/tratamiento farmacológico , Córnea , Glicocálix , Pectinas
3.
Molecules ; 29(1)2023 Dec 20.
Artículo en Inglés | MEDLINE | ID: mdl-38202631

RESUMEN

Lycium barbarum polysaccharide (LBP) is the main active component of Fructus Lycii, exhibiting various biological activities. This study aims to explore the protective effects of LBP on human corneal epithelial cells (HCEC) and a rat corneal injury model. Potential target points for LBP improving corneal injury repair were screened from public databases, and functional and pathway enrichment analyses of core targets were conducted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Rat corneal alkali burns and HCEC oxidative stress injury models were established, and the results were validated through slit lamp examination, HE staining, TUNEL assay, immunofluorescence, CCK-8 assay, flow cytometry, scratch assay, and qRT-PCR methods. In the context of database retrieval, identification of 10 LBP monosaccharide components and 50 corneal injury repair-related targets was achieved. KEGG pathway analysis suggested that LBP might regulate the IL-17 and TNF signaling pathways through targets such as JUN, CASP3, and MMP9, thereby improving corneal damage. In vivo and in vitro experimental results indicated that LBP could reduce the increase of inflammation index scores (p < 0.05), inflammatory cell density (p < 0.01), TUNEL-positive cells (p < 0.01), corneal opacity scores (p < 0.01), and expression of corneal stromal fibrosis-related proteins α-SMA, FN, and COL (p < 0.01) caused by chemical damage to rat corneas. LBP inhibited oxidative stress-induced decreases in cell viability (p < 0.001) and migration healing ability (p < 0.01) in HCECs, reducing apoptosis rates (p < 0.001), ROS levels (p < 0.001), and the expression of inflammatory factors TNF-α and IL-6 (p < 0.01). qRT-PCR results demonstrated that LBP intervention decreased the mRNA levels of JUN, CASP3, and MMP9 in H2O2-induced alkaline-burned corneas and HCECs (p < 0.01).The integrated results from network pharmacology and validation experiments suggest that the inhibitory effects of LBP on apoptosis, inflammation, and fibrosis after corneal injury may be achieved through the suppression of the TNF and IL-17 signaling pathways mediated by JUN, CASP3, and MMP9.


Asunto(s)
Lesiones de la Cornea , Medicamentos Herbarios Chinos , Interleucina-17 , Humanos , Animales , Ratas , Caspasa 3 , Metaloproteinasa 9 de la Matriz , Peróxido de Hidrógeno , Córnea , Lesiones de la Cornea/tratamiento farmacológico , Fibrosis , Inflamación/tratamiento farmacológico
4.
Sci Rep ; 11(1): 6909, 2021 03 25.
Artículo en Inglés | MEDLINE | ID: mdl-33767351

RESUMEN

We compared the therapeutic effects of topical 8-oxo-2'-deoxyguanosine (8-oxo-dG) and corticosteroid in a murine ocular alkali burn model. (n = 128) The corneal alkali burn model was established by applying 0.1 N sodium hydroxide (NaOH), followed by treatment with 8-oxo-dG, 0.1% fluorometholone (FML), 1% prednisolone acetate (PDE), or phosphate-buffered saline (PBS) twice daily. One week later, the clinical and histological status of the cornea were assessed. Transcript levels of inflammatory cytokines and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase as well as the levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the cornea, were assayed. The 8-oxo-dG and PDE groups showed marked improvements in corneal integrity and clarity when compared with the PBS group (each p < 0.01). The numbers of cells stained for neutrophil elastase and F4/80-positive inflammatory cells were significantly decreased, with levels of interleukin(IL)-1ß, IL-6, tumor necrosis factor(TNF)-α, and total ROS/RNS amounts markedly reduced in the 8-oxo-dG, FML, and PDE groups (each p < 0.05). Levels of NADPH oxidase type 2 and 4 were substantially more repressed in the 8-oxo-dG-treated group than in the PDE-treated group (each p < 0.05). Topical 8-oxo-dG showed excellent therapeutic effects that were comparable with those treated with topical PDE in a murine ocular alkali burn model.


Asunto(s)
8-Hidroxi-2'-Desoxicoguanosina/uso terapéutico , Quemaduras Químicas/tratamiento farmacológico , Lesiones de la Cornea/tratamiento farmacológico , Quemaduras Oculares/inducido químicamente , Fluorometolona/uso terapéutico , Glucocorticoides/uso terapéutico , Administración Oftálmica , Animales , Evaluación Preclínica de Medicamentos , Femenino , Ratones Endogámicos BALB C , Hidróxido de Sodio
5.
Int J Mol Med ; 46(6): 1951-1957, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33125502

RESUMEN

Curcumin has been used since ancient times as a treatment for a wide range of pathologies. For centuries, it has been considered to be an effective aid for common human diseases. Curcuma longa has been reported to possess various beneficial properties and actions, including anti­inflammatory, proapoptotic, antiangiogenic and cortisone­like actions. Pterygium is a degenerative disorder of the conjunctiva indicative of a strong inflammatory condition that requires surgical treatment, which often results in disfiguring sclerocorneal scars. The delay in the healing of superficial corneal wounds caused by topical administration of light­cortisone results in improved restoration of corneal functions and anatomy compared with physiological healing processes. The present review is focused on the medicinal properties of curcumin, the main component of Curcuma longa extract, in particular its strong cortisone­like effect, and its potential use for the prevention and treatment of sclerocorneal scars resulting from pterygium surgical excision.


Asunto(s)
Cicatriz/tratamiento farmacológico , Cicatriz/etiología , Lesiones de la Cornea/tratamiento farmacológico , Lesiones de la Cornea/etiología , Extractos Vegetales/uso terapéutico , Pterigion/complicaciones , Pterigion/cirugía , Animales , Cortisona/farmacología , Cortisona/uso terapéutico , Curcuma/efectos adversos , Humanos , Extractos Vegetales/efectos adversos , Extractos Vegetales/farmacología , Cicatrización de Heridas/efectos de los fármacos
6.
Invest Ophthalmol Vis Sci ; 59(12): 4821-4830, 2018 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-30347076

RESUMEN

Purpose: To study corneal wound healing after two cross-linking techniques using either rose bengal and green light (RGX) or the conventional treatment using riboflavin and UVA radiation (UVX). Methods: Corneas of New Zealand rabbits were monolaterally treated with UVX (21 eyes) or RGX (25 eyes). Treatments involved corneal de-epithelialization (8-mm diameter), soaking with photosensitizer (0.1% riboflavin in 20% dextran for 30 minutes for UVX; 0.1% rose bengal for 2 minutes for RGX), and light irradiation (370 nm, 3 mW/cm2, 30 minutes for UVX; 532 nm, 0.25 W/cm2, 7 minutes for RGX). Contralateral eyes were used as controls. Clinical follow-up included fluorescein staining, haze measurement, and pachymetry. Healing events analyzed after euthanasia at 2, 30, and 60 days included cell death (TUNEL assay), cell proliferation (BrdU [bromodeoxyuridine] immunofluorescence), and differentiation to myofibroblasts (α-SMA [alpha smooth muscle actin] immunohistochemistry). Results: Re-epithelialization and pachymetries were similar after RGX and UVX. The haze from day 1 to 15 was greater after UVX. Cell death was deeper after UVX, being localized in the anterior and middle stroma, and was superficial (anterior third) after RGX. Cell proliferation appeared after 2 days and was localized in the middle and posterior stroma in the UVX group but was superficial in the RGX group. After 60 days the number of stromal cells had not returned to the control number in either group. Conclusions: The deeper and longer-lasting cell damage caused by UVX compared to RGX may underlie the slower cell repopulation after UVX and other differences in healing. Shallower damage and a shorter treatment time suggest that RGX may be appropriate for stiffening thin corneas.


Asunto(s)
Lesiones de la Cornea/tratamiento farmacológico , Reactivos de Enlaces Cruzados , Colorantes Fluorescentes/uso terapéutico , Fármacos Fotosensibilizantes/uso terapéutico , Riboflavina/uso terapéutico , Rosa Bengala/uso terapéutico , Cicatrización de Heridas/efectos de los fármacos , Animales , Recuento de Células , Proliferación Celular/fisiología , Lesiones de la Cornea/fisiopatología , Paquimetría Corneal , Modelos Animales de Enfermedad , Epitelio Corneal/fisiología , Femenino , Etiquetado Corte-Fin in Situ , Luz , Conejos , Repitelización/fisiología , Rayos Ultravioleta , Cicatrización de Heridas/fisiología
7.
PLoS One ; 12(5): e0178030, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28542418

RESUMEN

PURPOSE: Ocular surface and corneal epithelial wounds are common and potentially debilitating problems. Ideal treatments for these injuries would promote epithelial healing without inflammation, infection and scarring. In addition the best treatments would be cost-efficient, effective, non-toxic and easily applied. Histatin-1 peptides have been shown to be safe and effective enhancers of epithelial wound healing in other model systems. We sought to determine whether histatin-1 peptides could enhance human corneal epithelial wound healing in vitro. METHODS: Histatin-1 peptides were applied to human corneal epithelial cells and compared over useful dose ranges in scratch assays using time-lapse microscopy. In addition, path finding analysis, cell spreading assays, toxicity and proliferation assays were performed to further characterize the effects of histatin-1 peptide on human corneal limbal epithelial (HCLE). RESULTS: Histatin-1 enhanced human corneal epithelial wound healing in typical wound healing models. There was minimal toxicity and no significant enhancement of proliferation of corneal epithelium in response to histatin-1 application. Corneal epithelial spreading and pathfinding appeared to be enhanced by the application of histatin-1 peptides. CONCLUSIONS: Histatin -1 peptide may enhance migration of HCLE cells and wound healing in vitro. These peptides may have benefit in corneal epithelial wounds and need to be investigated further.


Asunto(s)
Lesiones de la Cornea/tratamiento farmacológico , Epitelio Corneal/efectos de los fármacos , Histatinas/farmacología , Sustancias Protectoras/farmacología , Repitelización/efectos de los fármacos , Análisis de Varianza , Bromodesoxiuridina , Movimiento Celular/efectos de los fármacos , Movimiento Celular/fisiología , Proliferación Celular/efectos de los fármacos , Proliferación Celular/fisiología , Células Cultivadas , Lesiones de la Cornea/metabolismo , Lesiones de la Cornea/patología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Epitelio Corneal/metabolismo , Epitelio Corneal/patología , Técnica del Anticuerpo Fluorescente , Histatinas/síntesis química , Histatinas/toxicidad , Humanos , Sustancias Protectoras/síntesis química , Sustancias Protectoras/toxicidad , Repitelización/fisiología
8.
Int Immunopharmacol ; 48: 126-134, 2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28501766

RESUMEN

Cornea is an avascular transparent tissue. Ocular trauma caused by a corneal alkali burn induces corneal neovascularization (CNV), inflammation, and fibrosis, leading to vision loss. The purpose of this study was to examine the effects of Zerumbone (ZER) on corneal wound healing caused by alkali burns in mice. CNV was induced by alkali-burn injury in BALB/C female mice. Topical ZER (three times per day, 3µl each time, at concentrations of 5, 15, and 30µM) was applied to treat alkali-burned mouse corneas for 14 consecutive days. Histopathologically, ZER treatment suppressed alkali burn-induced CNV and decreased corneal epithelial defects induced by alkali burns. Corneal tissue treated with ZER showed reduced mRNA levels of pro-angiogenic genes, including vascular endothelial growth factor, matrix metalloproteinase-2 and 9, and pro-fibrotic factors such as alpha smooth muscle actin and transforming growth factor-1 and 2. Immunohistochemical analysis demonstrated that the infiltration of F4/80 and/or CCR2 positive cells was significantly decreased in ZER-treated corneas. ZER markedly inhibited the mRNA and protein levels of monocyte chemoattractant protein-1 (MCP-1) in human corneal fibroblasts and murine peritoneal macrophages. Immunoblot analysis revealed that ZER decreased the activation of signal transducer and activator of transcription 3 (STAT3), with consequent reduction of MCP-1 production by these cells. In conclusion, topical administration of ZER accelerated corneal wound healing by inhibition of STAT3 and MCP-1 production.


Asunto(s)
Quemaduras Químicas/tratamiento farmacológico , Lesiones de la Cornea/tratamiento farmacológico , Neovascularización de la Córnea/tratamiento farmacológico , Quemaduras Oculares/tratamiento farmacológico , Sesquiterpenos/uso terapéutico , Álcalis , Animales , Quemaduras Químicas/metabolismo , Quemaduras Químicas/patología , Línea Celular , Células Cultivadas , Quimiocina CCL2/antagonistas & inhibidores , Quimiocina CCL2/genética , Quimiocina CCL2/metabolismo , Córnea/efectos de los fármacos , Córnea/metabolismo , Córnea/patología , Lesiones de la Cornea/inducido químicamente , Lesiones de la Cornea/metabolismo , Lesiones de la Cornea/patología , Neovascularización de la Córnea/inducido químicamente , Neovascularización de la Córnea/metabolismo , Neovascularización de la Córnea/patología , Quemaduras Oculares/inducido químicamente , Quemaduras Oculares/metabolismo , Quemaduras Oculares/patología , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Humanos , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/metabolismo , Ratones Endogámicos BALB C , Factor de Transcripción STAT3/antagonistas & inhibidores , Factor de Transcripción STAT3/metabolismo , Sesquiterpenos/farmacología , Cicatrización de Heridas/efectos de los fármacos
9.
Am J Pathol ; 187(6): 1327-1342, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28412300

RESUMEN

Alkali burns to the eye constitute a leading cause of worldwide blindness. In recent case series, corneal transplantation revealed unexpected damage to the retina and optic nerve in chemically burned eyes. We investigated the physical, biochemical, and immunological components of retinal injury after alkali burn and explored a novel neuroprotective regimen suitable for prompt administration in emergency departments. Thus, in vivo pH, oxygen, and oxidation reduction measurements were performed in the anterior and posterior segment of mouse and rabbit eyes using implantable microsensors. Tissue inflammation was assessed by immunohistochemistry and flow cytometry. The experiments confirmed that the retinal damage is not mediated by direct effect of the alkali, which is effectively buffered by the anterior segment. Rather, pH, oxygen, and oxidation reduction changes were restricted to the cornea and the anterior chamber, where they caused profound uveal inflammation and release of proinflammatory cytokines. The latter rapidly diffuse to the posterior segment, triggering retinal damage. Tumor necrosis factor-α was identified as a key proinflammatory mediator of retinal ganglion cell death. Blockade, by either monoclonal antibody or tumor necrosis factor receptor gene knockout, reduced inflammation and retinal ganglion cell loss. Intraocular pressure elevation was not observed in experimental alkali burns. These findings illuminate the mechanism by which alkali burns cause retinal damage and may have importance in designing therapies for retinal protection.


Asunto(s)
Quemaduras Químicas/metabolismo , Quemaduras Oculares/metabolismo , Retina/lesiones , Álcalis , Animales , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Quemaduras Químicas/tratamiento farmacológico , Quemaduras Químicas/etiología , Quemaduras Químicas/patología , Córnea/inmunología , Lesiones de la Cornea/tratamiento farmacológico , Lesiones de la Cornea/etiología , Lesiones de la Cornea/metabolismo , Lesiones de la Cornea/patología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Quemaduras Oculares/tratamiento farmacológico , Quemaduras Oculares/etiología , Quemaduras Oculares/patología , Concentración de Iones de Hidrógeno , Infliximab/farmacología , Infliximab/uso terapéutico , Ratones Endogámicos C57BL , Ratones Noqueados , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Oxidación-Reducción , Conejos , Receptores Tipo I de Factores de Necrosis Tumoral/deficiencia , Receptores Tipo I de Factores de Necrosis Tumoral/genética , Receptores Tipo II del Factor de Necrosis Tumoral/deficiencia , Receptores Tipo II del Factor de Necrosis Tumoral/genética , Retina/inmunología , Retina/metabolismo , Retina/patología , Células Ganglionares de la Retina/efectos de los fármacos , Células Ganglionares de la Retina/patología , Hidróxido de Sodio , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/metabolismo , Úvea/metabolismo , Uveítis Anterior/inducido químicamente , Uveítis Anterior/metabolismo , Uveítis Anterior/patología , Uveítis Anterior/prevención & control
10.
J Vet Sci ; 18(3): 387-397, 2017 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-27586470

RESUMEN

Ginseng gintonin is an exogenous ligand of lysophosphatidic acid (LPA) receptors. Accumulating evidence shows LPA helps in rapid recovery of corneal damage. The aim of this study was to evaluate the therapeutic efficacy of gintonin in a rabbit model of corneal damage. We investigated the signal transduction pathway of gintonin in human corneal epithelium (HCE) cells to elucidate the underlying molecular mechanism. We next evaluated the therapeutic effects of gintonin, using a rabbit model of corneal damage, by undertaking histochemical analysis. Treatment of gintonin to HCE cells induced transient increases of [Ca2+]i in concentration-dependent and reversible manners. Gintonin-mediated mobilization of [Ca2+]i was attenuated by LPA1/3 receptor antagonist Ki16425, phospholipase C inhibitor U73122, inositol 1,4,5-triphosphate receptor antagonist 2-APB, and intracellular Ca2+ chelator BAPTA-AM. Gintonin facilitated in vitro wound healing in a concentration-dependent manner. When applied as an eye-drop to rabbits with corneal damage, gintonin rapidly promoted recovery. Histochemical analysis showed gintonin decreased corneal apoptosis and increased corneal cell proliferation. We demonstrated that LPA receptor activation by gintonin is linked to in vitro and in vivo therapeutic effects against corneal damage. Gintonin can be applied as a clinical agent for the rapid healing of corneal damage.


Asunto(s)
Lesiones de la Cornea/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Cicatrización de Heridas/efectos de los fármacos , Animales , Western Blotting/veterinaria , Calcio/metabolismo , Células Cultivadas , Córnea/efectos de los fármacos , Córnea/patología , Lesiones de la Cornea/patología , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Conejos , Receptores del Ácido Lisofosfatídico/efectos de los fármacos
11.
Glycoconj J ; 34(3): 325-338, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-27924424

RESUMEN

The importance of extracellular matrix (ECM) integrity in maintaining normal tissue function is highlighted by numerous pathologies and situations of acute and chronic injury associated with dysregulation or destruction of ECM components. Heparan sulfate (HS) is a key component of the ECM, where it fulfils important functions associated with tissue homeostasis. Its degradation following tissue injury disrupts this delicate equilibrium and may impair the wound healing process. ReGeneraTing Agents (RGTA®s) are polysaccharides specifically designed to replace degraded HS in injured tissues. The unique properties of RGTA® (resistance to degradation, binding and protection of ECM structural and signaling proteins, like HS) permit the reconstruction of the ECM, restoring both structural and biochemical functions to this essential substrate, and facilitating the processes of tissue repair and regeneration. Here, we review 25 years of research surrounding this HS mimic, supporting the mode of action, pre-clinical studies and therapeutic efficacy of RGTA® in the clinic, and discuss the potential of RGTA® in new branches of regenerative medicine.


Asunto(s)
Materiales Biomiméticos/farmacología , Lesiones de la Cornea/tratamiento farmacológico , Glicosaminoglicanos/farmacología , Sustancias Protectoras/farmacología , Piel/efectos de los fármacos , Cicatrización de Heridas/efectos de los fármacos , Animales , Materiales Biomiméticos/química , Huesos/efectos de los fármacos , Huesos/lesiones , Ensayos Clínicos como Asunto , Lesiones de la Cornea/rehabilitación , Evaluación Preclínica de Medicamentos , Matriz Extracelular/química , Tracto Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/lesiones , Glicosaminoglicanos/química , Heparitina Sulfato/química , Heparitina Sulfato/farmacología , Humanos , Músculos/efectos de los fármacos , Músculos/lesiones , Sustancias Protectoras/química , Medicina Regenerativa/métodos , Piel/lesiones , Andamios del Tejido
12.
BMC Complement Altern Med ; 16: 76, 2016 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-26912349

RESUMEN

BACKGROUND: This study aimed to evaluate the effects of Gelam honey on corneal keratocytes proliferative capacity and phenotypic characterization via MTT assay, gene expression and immunocytochemistry. METHODS: Corneal keratocytes from New Zealand white rabbits were cultured in basal medium (BM) and serum enriched medium (BMS). Serial dilutions of Gelam honey (GH) were added to both media and cells were cultured until passage 1. MTT assay was performed on corneal keratocytes in both media to ascertain the optimal dose of GH that produced maximum proliferation. RESULTS: Gelam honey at the concentration of 0.0015% in both media showed the highest proliferative capacity with no morphological changes compared to their respective controls. The gene expression of aldehyde dehydrogenase (ALDH), a marker for quiescent keratocytes and vimentin, a marker for fibroblast, were higher in the GH enriched groups. The alpha smooth muscle actin (α-SMA) expression, marker for myofibroblast, was lower in GH treated groups compared to the controls. Immunocytochemistry results were in accordance to the gene expression analyses. CONCLUSION: Gelam honey at a concentration of 0.0015% promotes ex vivo corneal keratocytes proliferation while retaining desirable phenotype expression. The results serve as a basis for the development of Gelam honey as a potential natural product in promoting corneal wound healing.


Asunto(s)
Proliferación Celular/efectos de los fármacos , Córnea/efectos de los fármacos , Lesiones de la Cornea , Queratocitos de la Córnea/efectos de los fármacos , Miel , Fenotipo , Cicatrización de Heridas , Actinas/genética , Actinas/metabolismo , Aldehído Deshidrogenasa/genética , Aldehído Deshidrogenasa/metabolismo , Animales , Apiterapia , Células Cultivadas , Córnea/citología , Lesiones de la Cornea/tratamiento farmacológico , Lesiones de la Cornea/genética , Lesiones de la Cornea/metabolismo , Fibroblastos , Expresión Génica/efectos de los fármacos , Conejos , Vimentina/genética , Vimentina/metabolismo , Cicatrización de Heridas/efectos de los fármacos
13.
J Travel Med ; 23(2): tav030, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26883926

RESUMEN

A 20-year-old male soldier was hit by the jellyfish. The ophthalmic examination revealed that epithelial keratitis and corneal oedema in the right eye. We prescribed 3% NaCl eyedrops and 0.3% Norfloxacin eyedrops in the treatment of the corneal jellyfish stings. Two weeks later, the cornea in the right eye healed. In this case report, 3% NaCl eyedrops was effective in the treatment of acute phase of jellyfish stings of the cornea.


Asunto(s)
Mordeduras y Picaduras/diagnóstico , Lesiones de la Cornea/diagnóstico , Soluciones Oftálmicas/uso terapéutico , Solución Salina Hipertónica/uso terapéutico , Escifozoos , Animales , Brazo , Mordeduras y Picaduras/tratamiento farmacológico , Lesiones de la Cornea/tratamiento farmacológico , Diagnóstico Diferencial , Humanos , Masculino , Medicina Militar , Personal Militar , Soluciones Oftálmicas/administración & dosificación , Solución Salina Hipertónica/administración & dosificación , Adulto Joven
14.
Mol Neurobiol ; 52(2): 990-1014, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26048672

RESUMEN

Platelet-rich plasma (PRP) has been tested in vitro, in animal models, and clinically for its efficacy in enhancing the rate of wound healing, reducing pain associated with injuries, and promoting axon regeneration. Although extensive data indicate that PRP-released factors induce these effects, the claims are often weakened because many studies were not rigorous or controlled, the data were limited, and other studies yielded contrary results. Critical to assessing whether PRP is effective are the large number of variables in these studies, including the method of PRP preparation, which influences the composition of PRP; type of application; type of wounds; target tissues; and diverse animal models and clinical studies. All these variables raise the question of whether one can anticipate consistent influences and raise the possibility that most of the results are correct under the circumstances where PRP was tested. This review examines evidence on the potential influences of PRP and whether PRP-released factors could induce the reported influences and concludes that the preponderance of evidence suggests that PRP has the capacity to induce all the claimed influences, although this position cannot be definitively argued. Well-defined and rigorously controlled studies of the potential influences of PRP are required in which PRP is isolated and applied using consistent techniques, protocols, and models. Finally, it is concluded that, because of the purported benefits of PRP administration and the lack of adverse events, further animal and clinical studies should be performed to explore the potential influences of PRP.


Asunto(s)
Axones/efectos de los fármacos , Dolor/tratamiento farmacológico , Plasma Rico en Plaquetas , Regeneración/efectos de los fármacos , Cicatrización de Heridas/efectos de los fármacos , Animales , Infecciones Bacterianas/tratamiento farmacológico , Ensayos Clínicos como Asunto , Lesiones de la Cornea/tratamiento farmacológico , Evaluación Preclínica de Medicamentos , Células Epiteliales/efectos de los fármacos , Fibroblastos/trasplante , Fracturas Óseas/tratamiento farmacológico , Humanos , Técnicas In Vitro , Péptidos y Proteínas de Señalización Intercelular/sangre , Péptidos y Proteínas de Señalización Intercelular/uso terapéutico , Ligamentos/lesiones , Trasplante de Células Madre Mesenquimatosas , Modelos Animales , Neovascularización Fisiológica/efectos de los fármacos , Plasma Rico en Plaquetas/química , Traumatismos de los Tendones/tratamiento farmacológico
15.
Arch Soc Esp Oftalmol ; 90(10): 467-74, 2015 Oct.
Artículo en Inglés, Español | MEDLINE | ID: mdl-26101128

RESUMEN

OBJECTIVE: The purpose of this study is to assess the effectiveness of the topical application of cacicol regenerating agent (RGTA) in an experimental model of corneal ulcer after photorefractive keratectomy (PRK) in mice. METHODS: Mice were subjected to PRK surgery with a 2.0mm ablation zone on the central cornea and 45mm of depth on a VISX Star S2 excimer laser. Corneas were treated topically with cacicol drops 1hour and 48hours after injury. Control groups received balanced salt solution (BSS) in the same dosage. Clinical and histopathological events were evaluated at 1, 2, 3 and 7 days after surgery. Sections obtained through the central region of the corneas were used to analyze the histopathological events of injured and healed corneas. αSMA (myofibroblast transformation), E cadherin (assembly of epithelial cells) and neuronal class III ß-tubulin (innervation) were performed. RESULTS: Corneas treated topically with cacicol for 7 days showed a greater degree of transparency compared to controls. cacicol treated corneas showed improved epithelial cytoarchitecture. Analysis of αSMA profiles in the stroma showed that cacicol reduced or delayed the presence of myofibroblasts in the stroma compared to BSS (P<0.001). Finally, a putative neuroregenerative effect of cacicol was found in corneas subjected to an experimental PRK lesion. In some cases some interindividual variability could be observed due to the design of the experimental model. This is a limitation to consider, despite the statistical significance of the data. CONCLUSIONS: In a model of laser induced surgical lesions in the cornea, topical application of an RGTA (i.e. cacicol) could be involved in avoiding myofibroblast scarring formation and promoting nerve regeneration.


Asunto(s)
Materiales Biomiméticos/uso terapéutico , Lesiones de la Cornea/tratamiento farmacológico , Úlcera de la Córnea/tratamiento farmacológico , Glicosaminoglicanos/uso terapéutico , Queratectomía Fotorrefractiva/efectos adversos , Complicaciones Posoperatorias/tratamiento farmacológico , Cicatrización de Heridas/efectos de los fármacos , Animales , Materiales Biomiméticos/administración & dosificación , Cicatriz/prevención & control , Lesiones de la Cornea/etiología , Úlcera de la Córnea/etiología , Evaluación Preclínica de Medicamentos , Epitelio Corneal/fisiología , Proteínas del Ojo/análisis , Glicosaminoglicanos/administración & dosificación , Láseres de Excímeros , Ratones , Ratones Endogámicos C57BL , Regeneración Nerviosa/efectos de los fármacos , Soluciones Oftálmicas , Complicaciones Posoperatorias/etiología , Regeneración/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA